Abstract:Medullary thyroid carcinoma (MTC) is a rare type of thyroid malignancy that accounts for approximately 1–2% of all thyroid cancers (TCs). MTC include hereditary and sporadic cases, the former derived from a germline mutation of rearrangement during transfection (RET) proto-oncogene, whereas somatic RET mutations are frequently present in the latter. Surgery is the standard treatment for early stage MTC, and the 10-year survival rate of early MTC is over 80%. While for metastatic MTC, chemotherapy showing low response rate, and there was a lack of effective systemic therapies in the past. Due to the high risk (ca. 15–20%) of distant metastasis and limited systemic therapies, the 10-year survival rate of patients with advanced MTC was only 10–40% from the time of first metastasis. Over the past decade, targeted therapy for RET has developed rapidly, bringing hopes to patients with advanced and progressive MTC. Two multi-kinase inhibitors (MKIs) including Cabozantinib and Vandetanib have been shown to increase progression-free survival (PFS) for patients with metastatic MTC and have been approved as choices of first-line treatment. However, these MKIs have not prolonged overall survival (OS) and their utility is limited due to high rates of off-target toxicities. Recently, new generation TKIs, including Selpercatinib and Pralsetinib, have demonstrated highly selective efficacy against RET and more favorable side effect profiles, and gained approval as second-line treatment options. Despite the ongoing development of RET inhibitors, the management of advanced and progressive MTC remains challenging, drug resistance remains the main reason for treatment failure, and the mechanisms are still unclear. Besides, new promising therapeutic approaches, such as novel drug combinations and next generation RET inhibitors are under development. Herein, we overview the pathogenesis, molecular genetics and current management approaches of MTC, and focus on the recent advances of RET inhibitors, summarize the current situation and unmet needs of these RET inhibitors in MTC, and provide an overview of novel strategies for optimizing therapeutic effects.

The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer

The importance of the RET gene in thyroid cancer and therapeutic implications

Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions

RET Kinase Inhibitors for the Treatment of RET -altered Thyroid Cancers: Current Knowledge and Future Directions

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives

Precision therapy for RET-altered cancers with RET inhibitors

Targeting RET mutation in medullary thyroid cancer

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations

Precious Gene: The Application of RET-Altered Inhibitors

REThinking the role of the RET oncogene in breast cancer

Identifying novel oncogenic <i>RET</i> mutations and characterising their sensitivity to RET-specific inhibitors

ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer Via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2

Cheminformatics-based identification of phosphorylated RET tyrosine kinase inhibitors for human cancer

Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer

Targeting RET-rearranged non-small-cell lung cancer: future prospects

Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.

Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose